Top Pharma Companies on Facebook
Back in August, 2011, Facebook opened up comments on ALL pharma pages, which meant that the pharmaceutical industry no longer was able to shut off comments on their product-related pages. Consequently, several companies decided to shut down their pages (read, for example, "Pharma Facebook Pages Being Phased Out" and "Janssen to Shut Down Psoriasis 360 FaceBook Page" ).These days Facebook offers new opportunities and tools for the pharmaceutical industry to do promotions such as disease awareness campaigns (e.g., "Novartis, Queen Latifah,& American Heart Association Team Up on Facebook Live Broa...
Source: Pharma Marketing Blog - January 12, 2017 Category: Pharmaceuticals Tags: FaceBook Source Type: blogs

Does A ‘One-Size-Fits-All’ Formulary Policy Make Sense?
Over the last decade, insurers have increasingly used step therapy, or “fail-first,” policies as a strategy to contain pharmaceutical costs. Step therapy requires patients to begin treatment for a medical condition on a typically less expensive drug, and only progress to more costly second-line drugs when the first-line therapy becomes ineffective or inappropriate. Step therapy shifts clinical decision-making away from physicians and toward centralized policies that define treatment steps for patient populations based on the potential for more cost-effective care. The rapid growth in the use of step therapy pol...
Source: Health Affairs Blog - June 2, 2016 Category: Health Management Authors: Adrienne Chung, Joanna MacEwan and Dana Goldman Tags: Costs and Spending Drugs and Medical Technology Equity and Disparities Health Policy Lab Health Professionals Insurance and Coverage Payment Policy Quality Prescription Drugs step therapy Source Type: blogs

The Need For Publicly Funded Trials To Get Unbiased Comparative Effectiveness Data
Comparative effectiveness research was one of the hotly debated components of the Affordable Care Act. The pharmaceutical industry is marketing driven, with pharmaceutical companies spending more on marketing than they do on research and development. The need for a marketing edge can also drive drug development. As illustrated by the discussion below of Gazyva and Nexium, drugs can be developed at higher doses than the drugs they are intended to replace. When the newer, higher-dose drugs are tested against the older, lower-dose drugs, the trials are intended to show that the newer, higher dose drugs are superior to the old...
Source: Health Affairs Blog - February 20, 2015 Category: Health Management Authors: Robert Bohrer Tags: All Categories Business of Health Care Comparative Effectiveness Innovation Pharma Policy Research Source Type: blogs